Thursday, August 27, 2026
Court clears Lupin's generic Kalydeco in Vertex patent fight
A Delaware federal court ruled on August 24 that Lupin's proposed generic version of Vertex's cystic fibrosis drug Kalydeco does not infringe Vertex's patents, finding Lupin's 74% ivacaftor formulation falls outside the patents' claimed 80% concentration range. The ruling clears a path for Lupin, which already holds tentative FDA approval, to launch the first generic challenger to a Vertex CF modulator pending final FDA approval.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- Rival's cystic fibrosis drug fails, Vertex shares gainThursday, August 13, 2026
- Vertex tops Q2 estimates, raises 2026 revenue guidanceTuesday, August 4, 2026
- Vertex pays AbCellera $28M upfront for autoimmune T-cell engagersFriday, July 31, 2026
- Vertex to buy Crinetics for ~$10B in largest-ever dealWednesday, July 8, 2026